Mayzent (Siponimod) for Multiple Sclerosis

Last updated May 9, 2022, by Teresa Carvalho, MS

Fact-checked by Ines Martins, PhD

FAQs about Mayzent

Mayzent was approved by the U.S. Food and Drug Administration in March 2019 to treat adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.

Animal studies suggest that Mayzent can cause damage to a developing fetus. Anyone with the capacity to become pregnant should use effective birth control methods while on Mayzent and for 10 days after ceasing treatment.

Interactions between alcohol and Mayzent have not been reported. However, both can cause damage to the liver, and alcohol is also known to interfere with some disease symptoms and medications. It is recommended that patients discuss safe alcohol use with their healthcare team.

Benefits may be seen by some patients as soon as six months after starting treatment. In the BOLD trial, which compared Mayzent against a placebo in people with relapsing-remitting multiple sclerosis, significant reductions in the number of brain lesions and in relapse frequency were observed in as little as six months. However, as each person may respond very differently to a given medication, patients should talk with their care team to understand how Mayzent could help in their specific case.

Neither hair loss nor weight gain has been reported in clinical trials as side effects of Mayzent. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms while on the medication.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Related Articles

Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.